title: Pharmacological protein targets in polyglutamine diseases: mutant polypeptides and their interactors.
abstract: Polyglutamine diseases are a group of pathologies affecting different parts of the brain and causing dysfunction and atrophy of certain neural cell populations. These diseases stem from mutations in various cellular genes that result in the synthesis of proteins with extended polyglutamine tracts. In particular, this concerns huntingtin, ataxins, and androgen receptor. These mutant proteins can form oligomers, aggregates, and, finally, aggresomes with distinct functions and different degrees of cytotoxicity. In this review, we analyze the effects of different forms of polyQ proteins on other proteins and their functions, which are considered as targets for therapeutic intervention.
authors.affiliation: Institute of Cytology of Russian Academy of Sciences, Tikhoretsky pr., 4, St. Petersburg 194064, Russia.
authors.forename: Boris A
authors.initials: BA
authors.lastname: Margulis
authors.forename: Vladimir
authors.initials: V
authors.lastname: Vigont
authors.forename: Vladimir F
authors.initials: VF
authors.lastname: Lazarev
authors.forename: Elena V
authors.initials: EV
authors.lastname: Kaznacheyeva
authors.forename: Irina V
authors.initials: IV
authors.lastname: Guzhova
mesh_terms: D000818:Animals; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy / Q000378:metabolism; D058990:Molecular Targeted Therapy; D020966:Muscular Disorders, Atrophic / Q000188:drug therapy / Q000378:metabolism; D010455:Peptides / Q000235:genetics* / Q000378:metabolism; D017510:Protein Folding; D055503:Protein Multimerization; D057165:Proteostasis Deficiencies / Q000188:drug therapy / Q000378:metabolism; D020754:Spinocerebellar Ataxias / Q000188:drug therapy / Q000378:metabolism
chemical_list: D010455:Peptides; C097188:polyglutamine